Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionDilemma of first line regimens in metastatic pancreatic adenocarcinomaTranslational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expressionEnhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.Nucleoside analogs: ready to enter the era of precision medicine?Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under GemcitabineAstaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization.Future role of endoscopic ultrasound in personalized management of pancreatic cancer.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.
P2860
Q24273350-9FFC7A48-B6BB-44F5-AA15-0974F7117FB1Q28077147-3E365ED4-89AF-40B8-BC38-C8ED95462618Q34067863-2E37D287-DDCB-458C-9EDC-D7FA47F26D5AQ35812824-B2FBBE08-8988-48B7-BD53-3279C8F5D92FQ36342657-6A521CE4-0D8F-4C30-B24D-FEC30BD5D869Q37720259-3AADE681-9F85-4B48-8618-88C3B693129FQ38842938-7AF6FF7E-F2D7-445A-BA4A-72D993F2E036Q41487497-31B452F9-A1C9-4E27-B63E-55B554A018E2Q47128811-299EAAF4-DCCF-4B9B-8F60-F9F0333FCF7FQ47138141-1A1672AE-C813-4F1D-A316-762A34898B8FQ47830761-A7857D5E-7034-4A15-86B9-6E3896094FF9Q55361920-B1B84A97-6C48-48A1-B2B2-C3AD51F0EC1D
P2860
Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
@en
type
label
Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
@en
prefLabel
Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
@en
P2860
P356
P1476
Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
@en
P2093
Charles Dumontet
Lars Petter Jordheim
P2860
P304
P356
10.2217/BMM.13.48
P577
2013-08-01T00:00:00Z